RS58965B1 - Inhibitori arginaze i postupci upotrebe - Google Patents

Inhibitori arginaze i postupci upotrebe

Info

Publication number
RS58965B1
RS58965B1 RS20190839A RSP20190839A RS58965B1 RS 58965 B1 RS58965 B1 RS 58965B1 RS 20190839 A RS20190839 A RS 20190839A RS P20190839 A RSP20190839 A RS P20190839A RS 58965 B1 RS58965 B1 RS 58965B1
Authority
RS
Serbia
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
RS20190839A
Other languages
English (en)
Inventor
David W Christianson
Bruce Edward Tomczuk
Richard Scott Pottorf
Andrew Vargha Colasanti
Gary Lee Olson
Original Assignee
Univ Pennsylvania
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Astrazeneca Uk Ltd filed Critical Univ Pennsylvania
Publication of RS58965B1 publication Critical patent/RS58965B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
RS20190839A 2009-01-26 2010-01-26 Inhibitori arginaze i postupci upotrebe RS58965B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14727009P 2009-01-26 2009-01-26
EP10734002.8A EP2389352B1 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use
PCT/US2010/022090 WO2010085797A2 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
RS58965B1 true RS58965B1 (sr) 2019-08-30

Family

ID=42354317

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190839A RS58965B1 (sr) 2009-01-26 2010-01-26 Inhibitori arginaze i postupci upotrebe

Country Status (16)

Country Link
US (4) US20100189644A1 (sr)
EP (1) EP2389352B1 (sr)
JP (2) JP2012515799A (sr)
CA (1) CA2749853C (sr)
CY (1) CY1121815T1 (sr)
DK (1) DK2389352T3 (sr)
ES (1) ES2729474T3 (sr)
HR (1) HRP20191433T1 (sr)
HU (1) HUE046932T2 (sr)
LT (1) LT2389352T (sr)
PL (1) PL2389352T3 (sr)
PT (1) PT2389352T (sr)
RS (1) RS58965B1 (sr)
SI (1) SI2389352T1 (sr)
TR (1) TR201910726T4 (sr)
WO (1) WO2010085797A2 (sr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876955B (zh) * 2010-04-22 2018-11-23 马尔斯公司 精氨酸酶抑制剂及其治疗应用
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
CN104857005B (zh) * 2010-12-31 2019-04-26 阿斯利康公司 精氨酸酶抑制剂及其使用方法
WO2013056163A1 (en) * 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
BR112014009415B1 (pt) 2011-10-19 2021-11-23 Mars, Incorporated Composição farmacêutica, composto inbidor de arginase e seus usos
US10299377B2 (en) 2011-12-22 2019-05-21 Fujifilm Corporation Conductive sheet and touch panel
WO2013158262A1 (en) 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
KR102146673B1 (ko) * 2012-12-04 2020-08-21 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802830QA (en) * 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
UA125289C2 (uk) 2015-10-30 2022-02-16 Калітера Байосайєнсиз, Інк. Композиції і способи для інгібування активності аргінази
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2018074451A1 (ja) * 2016-10-17 2018-04-26 国立大学法人金沢大学 癌治療剤
WO2018089490A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
LT3559009T (lt) 2016-12-22 2021-06-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo slopinimui
PE20200339A1 (es) 2017-05-12 2020-02-14 Calithera Biosciences Inc Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
RU2695333C1 (ru) * 2018-09-24 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек ингибитором аргиназы II в эксперименте
RU2696580C1 (ru) * 2018-09-25 2019-08-05 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек ингибитором аргиназы II в эксперименте
SI3921033T1 (sl) * 2019-02-08 2023-11-30 Astrazeneca Ab Zaviralci arginaze in postopki njihove uporabe
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477391A (en) 1981-08-14 1984-10-16 Collins James F Amino acid isomers, their production and their medicinal use
CA2305703A1 (en) * 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
EP1351674A4 (en) * 2000-04-12 2004-12-22 Cornell Res Foundation Inc PHARMACOTHERAPY FOR VASCULAR DYSFUNCTION ASSOCIATED WITH THE DEFICIENT BIOACTIVITY OF NITRIC OXIDE
US20050203082A1 (en) * 2003-08-13 2005-09-15 Hsu Chung Y. Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
JP2010510257A (ja) * 2006-11-21 2010-04-02 レイクスウニフェルジテイト・フローニンゲン 喘息及びアレルギー性鼻炎の治療におけるアルギナーゼ阻害剤の使用

Also Published As

Publication number Publication date
DK2389352T3 (da) 2019-07-29
CA2749853A1 (en) 2010-07-29
EP2389352A4 (en) 2013-02-20
TR201910726T4 (tr) 2019-08-21
ES2729474T3 (es) 2019-11-04
EP2389352B1 (en) 2019-05-08
HUE046932T2 (hu) 2020-04-28
PT2389352T (pt) 2019-08-23
US20160194340A1 (en) 2016-07-07
SI2389352T1 (sl) 2019-08-30
LT2389352T (lt) 2019-06-10
HRP20191433T1 (hr) 2019-11-15
WO2010085797A3 (en) 2010-11-04
US20190127395A1 (en) 2019-05-02
JP6177832B2 (ja) 2017-08-09
CY1121815T1 (el) 2020-07-31
EP2389352A2 (en) 2011-11-30
US20200223871A1 (en) 2020-07-16
AU2010206535A1 (en) 2011-07-28
JP2015205891A (ja) 2015-11-19
JP2012515799A (ja) 2012-07-12
WO2010085797A2 (en) 2010-07-29
US20100189644A1 (en) 2010-07-29
US10118936B2 (en) 2018-11-06
CA2749853C (en) 2018-08-21
PL2389352T3 (pl) 2019-10-31

Similar Documents

Publication Publication Date Title
RS58965B1 (sr) Inhibitori arginaze i postupci upotrebe
HK1213769A1 (zh) 精氨酸酶抑制劑及其使用方法
IL240771A0 (en) Benzoxazole kinase inhibitors and methods of use
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
EP2379561A4 (en) MLK INHIBITORS AND METHODS OF USE
HK1160119A1 (en) Kinase inhibitors and methods of use
IL224389A (en) Demetylase inhibitors of arsylcyclopropylamine-based lsd1 and their medical use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
IL214226A (en) Inhibitors of beta-secretase and various related aspects thereof
HK1149933A1 (en) Diazacarbazoles and methods of use
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
IL209548A0 (en) Diazacarbazoles and methods of use
EP2344204A4 (en) TELOMERASE INHIBITOR AND METHOD OF USE THEREOF
ZA201301795B (en) Inhibitors of notum pectinacetylesterase and methods of their use
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
EP2393787A4 (en) CADHERINE 11 INHIBITORS AND METHOD FOR THEIR USE
EP2242367A4 (en) REL INHIBITORS AND METHODS OF USE
ZA201106083B (en) Inhibitors of viral integrase and methods of use
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法